EOM 1352: Fri 7 June 2024, 11:36

Current Edition

ramusmedical
news

Novel clinical trial to examine cannabis as potential treatment for essential tremor

Researchers at University of California School of Medicine are preparing to launch a novel clinical trial to examine the safety, efficacy and pharmacological properti...
Continue Reading →
Australasia

Study finds daily aspirin does not reduce heart attack risk

Daily, low dose asprin found to not minimise heart attack risk. Monash University in Australia has repo...
Continue Reading →
Europe

Positive Phase 3 results presented for Dupixent® (dupilumab) show significant improvement on multiple measures of disease severity in adolescents with moderate-to-severe atopic dermatitis

Results on skin clearing, itch and certain quality of life measurements were presented today as a late-breaking oral presentation at the 27th EADV Congress   Par...
Continue Reading →
Europe

Alzheimer’s disease: amyloid β protein once again in the spotlight as a therapeutic target

World Alzheimer's Day on 21 September 2018 (Vienna, 18 September 2018) For many years amyloid β protein was considered to be a promising therapeutic target in Alz...
Continue Reading →
Asia Pacific

GamaMabs Pharma starts a phase 2 study of monoclonal antibody GM102 in patients with advanced or metastatic colorectal cancer

C201 phase 2 will study immuno-enhancer antibody GM102, targeting AMHRII as a single agent and in combination with Trifluridine/Tipiracil (Lonsurf®) Paris and Toulou...
Continue Reading →
news

New malaria drug starts clinical trials

Release of malaria parasites from red blood cell. After decades a new drug against malaria has been develope...
Continue Reading →
news

Johns Hopkins scientists successfully perform 3D personalized virtual simulations of the heart

In a proof of concept study, scientists at Johns Hopkins report they have successfully performed 3D personalized virtual simulations of the heart to accurately identi...
Continue Reading →
Europe

Minoryx announces dosing of first US patient in phase 2/3 clinical study of min-102 (advance)

Mataró, Barcelona Spain – Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces the dosing of its first US...
Continue Reading →
Europe

FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events

Paris and Tarrytown, NY - September 12, 2018 - Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted a su...
Continue Reading →
news

Phase 2 clinical study reports best outcomes to date for older Hodgkin lymphoma patients

Recently published results of a phase 2 clinical trial have shown the best outcomes to date for newly diagnosed older Hodgkin lymphoma patients treated with brentuxim...
Continue Reading →
Quotient